Puma Biotechnology
PBYI
93 hedge funds and large institutions have $158M invested in Puma Biotechnology in 2024 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 26 reducing their positions, and 9 closing their positions.
2,100% more call options, than puts
Call options by funds: $4.64M | Put options by funds: $211K
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
89% more capital inflows, than outflows
Capital inflows: $36.6M | Capital outflows: $19.4M
38% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 26
13% more funds holding
Funds holding: 82 → 93 (+11)
5.76% more ownership
Funds ownership: 55.94% → 61.7% (+5.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Frazier Life Sciences Management
Palo Alto,
California
|
+$15.2M |
| 2 |
Goldman Sachs
New York
|
+$1.8M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$1.68M |
| 4 |
Jane Street
New York
|
+$1.57M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$6.22M |
| 2 |
ACM
Athyrium Capital Management
New York
|
-$2.88M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.67M |
| 4 |
EP
Eversept Partners
New York
|
-$1.45M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$1.02M |
PBYI Hedge Fund Activity: Q1 2024 in Review
93 of the 6,963 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q1 2024, worth a combined $158M — up 37% from $115M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PBYI positions and 9 closed out — a net gain of 11 holders — while 36 added to existing stakes and 26 trimmed.
The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $15.2M. The largest seller was Camber Capital Management, cutting an estimated $6.22M.
- 93 institutional investors held Puma Biotechnology (PBYI) as of Q1 2024, up from 82 in Q4 2023.
- Funds reported $158M of Puma Biotechnology stock for Q1 2024, up 37% quarter-over-quarter.
- 20 funds opened new Puma Biotechnology positions in Q1 2024 and 9 closed out, a net change of +11 holders.
- The largest Puma Biotechnology buyer in Q1 2024 was Frazier Life Sciences Management, an estimated $15.2M added.
- The largest Puma Biotechnology seller in Q1 2024 was Camber Capital Management, an estimated $6.22M sold.
Based on aggregated 13F filings for Q1 2024.